Regenerative Medical Technology (RMTG) Liabilities and Shareholders Equity (2017 - 2026)

Regenerative Medical Technology's Liabilities and Shareholders Equity history runs 10 years deep, the most recent figure standing at $5.0 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 25.84% year-over-year to $5.0 million; the TTM figure through Mar 2026 stood at $18.5 million (up 31.42% YoY), while the FY2025 annual figure was $4.5 million, up 17.46% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $5.0 million, up from $4.5 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $9.0 million in Q1 2022, with the low at $2.9 million in Q4 2023.
• The 5-year median for Liabilities and Shareholders Equity is $4.5 million (2025), against an average of $5.4 million.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity jumped 828.5% in 2022, then sank 64.37% in 2023.
• Regenerative Medical Technology's Liabilities and Shareholders Equity stood at $8.1 million in 2022, then tumbled by 64.37% to $2.9 million in 2023, then soared by 32.73% to $3.8 million in 2024, then advanced by 17.46% to $4.5 million in 2025, then climbed by 11.6% to $5.0 million in 2026.
• Business Quant data shows RMTG's Liabilities and Shareholders Equity at $5.0 million in Q1 2026, $4.5 million in Q4 2025, and $4.5 million in Q3 2025.